Purpose: The aim of this study is to assess the maternal outcomes and complications of deep venous thrombosis (DVT) encountered in early pregnancy, mainly regarding recurrence using different regimens of fondaparinux treatment periods, rather than mentioned in different studies and recommended by the royal and American Colleges of Obstetricians and Gynecologists, but with close surveillance program and frequent follow up visits and duplex US follow up of different patients groups. Methods: the study was conducted on 60 women with DVT presented during the 1st trimester of pregnancy in zagazig university hospitals; patients received fondaparinux therapeutic dose, until full clinical improvement and duplex complete recanalization, then the patients were randomly divided into 2 groups the 1st continued on a prophylactic dose of fondaparinux till the end of pregnancy and the other kept on aspirin 75 mg daily till beginning of 9th month where they received a prophylactic dose of fondaparinux till the end of pregnancy. After delivery all patients will be on warfarin for six weeks with target INR between two and three. All patients will be followed up for 24 weeks after labour with outcomes assessment of complications specifically recurrence. Results: the study was carried out during the period between June 2015 to June 2017; the mean age of the patients was 25.33±1.17 and 24.4±5.07 for both groups respectively. Level of DVT, maternal outcome including; DVT recanalization and complications such as recurrence (DVT and or PE) and post thrombotic syndrome (PTS) were compared between both groups. Conclusion: the low rate of recurrence in our study challenged the belief that all pregnant females with recanalized DVT should receive LMWH prophylaxis all throughout pregnancy; therefore we recommend fondaparinux prophylaxis from the beginning of the 9th month of pregnancy stopped 24 hours before labour and return to full therapeutic dose in the postpartum period with oral anticoagulant therapy (warfarin) till target INR is achieved, where fondaparinux is stopped and continue with warfarin for at least 6 weeks. Key words: deep venous thrombosis - pregnancy- fondaparinux.